Intellectual Product – Page 16

Senate Grills RFK Jr. on Controversial Health Stances in Contentious HHS Secretary Confirmation Hearings

5 months ago talkbio0Tagged Administration occupational activities, CHARGE Syndrome, Chronic disease, Confirmation, Hearings, public health policy, Robert F. Kennedy, Secretary Nomination, Senate, Skepticism, Transplant Registry Unified Management Program, Vaccines

Robert F. Kennedy Jr., HHS Secretary nomination, Senate confirmation hearings, vaccine skepticism, chronic disease focus, public health policy, Trump administration

RFK Jr. Faces Intense Scrutiny in Senate Confirmation Hearings for HHS Secretary

6 months ago talkbio0Tagged Confirmation, doubt, Health, Hearings, Human Services Secretary, Republican, Robert F. Kennedy, Senate, stance, Transplant Registry Unified Management Program, Vaccines

Robert F. Kennedy Jr., Senate confirmation hearings, Health and Human Services Secretary, Trump nominee, vaccine stance, Republican doubts

Amgen and Celltrion Reach Settlement in Denosumab Patent Litigation, Paving Way for Mid-2025 Biosimilar Launch

6 months ago talkbio0Tagged amgen, Biosimilars, Celltrion, denosumab, launch, Legal patent, Litigation, settlement

Amgen, Celltrion, denosumab, patent litigation, biosimilar, settlement, launch date

Trump 2.0: RFK Confirmation Hearings and Ongoing Clinical Trials Amidst Administrative Changes

6 months ago talkbio0Tagged Clinical Trials, Confirmation, Hearings, NIH Mouse, Partnership, Policy, RFK gene, Transplant Registry Unified Management Program

Trump 2.0, RFK Confirmation Hearings, Clinical Trials, NIH Grant Reviews, US-India Partnership, Second Term Policies

Vigil Neuroscience’s Oral Alzheimer’s Candidate VG-3927 Shows Promising Phase 1 Results with Sanofi’s Strategic Support

6 months ago talkbio0Tagged Agonist, Alzheimer 's disease, Clinical Trials, Microglia, Phase 1 (qualifier value), Programs - Publication Format, Sanofi Strategic, TREM2, VG-3927, Vigil

Vigil Neuroscience, VG-3927, Alzheimer’s disease, Phase 1 clinical trial, Sanofi strategic investment, TREM2 agonist program, Microglia therapy

Samsung Biologics Achieves Record Revenue and Secures Largest Contract to Date

6 months ago talkbio0Tagged Biological Factors, Biosimilars, CDMO, Contract agreement, Drug Industry, Largest, Revenue, Samsung

Samsung Biologics, Record Revenue, Largest Contract, Biosimilars, CDMO, Pharmaceutical Industry

Trump Revokes Biden’s Executive Order on AI Safety and Trustworthiness

6 months ago talkbio0Tagged Administration occupational activities, AI safety, Aortic Valve Insufficiency, Artificial (qualifier value), Biden Executive Order, governance, Regulation, Transplant Registry Unified Management Program

AI Safety, Biden Executive Order, Trump Administration, Artificial Intelligence Governance, AI Regulation

Trump’s Second Term: Mifepristone Battle Looms as Early Test of Abortion Stance

6 months ago talkbio0Tagged court, mifepristone, Reproduction, Supreme, Transplant Registry Unified Management Program, United States Food and Drug Administration, Unspecified Abortion

Mifepristone, abortion, Trump, second term, reproductive rights, FDA, Supreme Court

Sanofi Assures No Supply Disruptions Following FDA Warning Letter for US Manufacturing Site

6 months ago talkbio0Tagged Cautionary Warning, Cyclic GMP, deviations, interruptions, Letter [Publication Type], manufacturing site, sanofi, U.S., United States Food and Drug Administration

Sanofi, FDA warning letter, US manufacturing site, supply interruptions, CGMP deviations

Sionna and Odyssey Therapeutics Kick Off 2025 Biotech IPO Wave with SEC Filings

6 months ago talkbio0Tagged 2025, File (record), Health care facility, Industry, IPO, JPM, Market, Odyssey, Sionna

Sionna Therapeutics, Odyssey Therapeutics, IPO filings, biotech industry, JPM Healthcare Conference, 2025 IPO market